Progression free survival, overall survival and

Progression free survival, overall survival and H 89 supplier duration of response

were estimated according to the Kaplan-Meier method. We used the Cox proportional hazards regression model to estimate hazard ratios and 95% CIs. Differences between survival curves were tested for statistical significance with the two-sided log-rank test. Patients A total of 17 patients with IgD MM was identified, patients characteristics are listed in Table 1. The median age of the patients was 55-years (range 37-78); 8/17 patients had ECOG performance scores > 2 and 14 had ≥ 1 lytic bone lesions. Eight patients (47%) had renal impairment with estimated glomerular filtration rate (eGFR) < 50 ml/min, one patient had hypercalcemia (serum calcium concentration ≥ 12 mg/dl), 11 patients had lambda light chains (64%) and Bence-Jones proteinuria

in 70%. NSC23766 purchase Five patients were of stage III according to ISS; cytogenetic analysis by fluorescence in situ hybridization (FISH) was possible in six of eleven patients and the abnormalities are shown in Table 2. Only one patient was positive for amyloidosis at baseline. Table 1 Patient characteristics at Tofacitinib research buy diagnosis   Number of patients = 17 Male/Female 11/6 Median Age at diagnosis yr (range) 55 (37-78) years   ≤ 65 y = 13 (76.5%), ≥ 65 y = 4 (23.5%) ISS stage at diagnosis   I 7 II 2 III 5 Unknown 3 Performance status   ECOG < 2 9 ECOG > 2 8 Light chain type   k 6 λ 11 Bone marrow infiltration 30% (10-70%) Extra osseous disease 0 Bone lesions 14/17 (82%) Median serum monoclonal protein g/dl 1.05 (0.09-5) Median Urine monoclonal protein g/24 h 0.79 (0-28) Urine immunofixation positive 12/17 (70%) Serum β2 microglobulin > 5.5 mg/L 5/17 (29%) Serum albumin < 3.5 g/dl 5/17 (29%) eGFR < 50 ml/min 8/17 (47%) Serum

Calcium > 12 mg/dl 1/17 Amyloidosis 1/17 Hemoglobin g/dl, median (range) 11.9 (6.5-15) < 10 5/17 (29%) WBC count 109/L, median (range) 6.57 (3.19-16.8) > 7 × 109/L 7/17 (41%) Platelet count 109/L, median (range) 214 (74-518) < 100 × 109/L 1/17 Table 2 Interphase FISH cytogenetic profile results   Number of patients = 17 Not available 11 Available 6 del(13q) 1/6 del(6q) 1/6 t(11;14) 2/6 -Y 1/6 +11 1/6 Results Six patients were treated with CT, five with Melphalan plus steroids based regimens and one with VAD (Vincristine, Adriamycin and Dexametasone) Glutamate dehydrogenase plus CED (Cyclophosphamide, Etoposide, Dexamethasone); one patient showed a CR, two VGPR, two PR and one SD. Thalidomide was used as maintenance in the patient who obtained CR after CT. The overall response rate (ORR) was 83%; after a median follow up of 38 months (range 19-60) for patient treated with conventional chemotherapy, the median OS was 34 months (95% CI 15- 54 months) and the median PFS was 18 months (95% CI 3-33 months). Median DOR was 7 months (95% CI 5-9 months). Eleven patients underwent HDT/ASCT, as part of their front line therapy, five patients received single and six tandem ASCT.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>